05 Jul 2017
Posted by Andrew Kantor
Each year we ask GPhA members for their ideas on laws that need to be enacted or changed. And those member ideas get turned into results.
You get the picture.
We’re about to look at the issues we’ll be working on in the 2018 legislative session.
If there’s a law or policy issue you want to see changed — something that will improve patient care or the practice of pharmacy — tell us about it!
E-mail a brief explanation of the issue to our VP of public policy, Greg Reybold, at firstname.lastname@example.org. Yes, it’s that simple.
Deadline: Thursday, July 27 by 5:00 p.m.
Greg compiles all your ideas. The best ones — chosen by our legislative policy committee and board of directors — will become part of our 2018 legislative agenda.
GPhA is your association. Our legislative agenda needs to reflect your idea and your needs. We want your opinion heard. So get e-mailing!
Here’s the story of how Georgia and other states are trying to keep up with all the new opioids appearing on the streets.
At the Georgia Bureau of Investigation’s forensic lab outside Macon, [lab director Brian] Hargett assigned the tablets to one of his forensic chemists. She threw on her gown and gloves, weighed a pill, and dropped it in a skinny vial to soak in ethanol. Then she ran a test designed to separate and identify each substance in the pill. Two synthetic opioids showed up — including one never before seen in Georgia.
Their best guess: the little-known, and lethal, compound known as cyclopropyl.
The Georgia Board of Pharmacy passed an emergency rule regulating a new kind of synthetic opioid — tetrahydrofuran fentanyl — as a Schedule 1 substance. This is the kind that is quickly absorbed through the skin and is resistant to naloxone, too.
Kudos to the BoP for giving police the authority to seize it.
Oklahoma is the latest state to join the Sue the Opioid Manufacturers Club™.
In New Hampshire, opioid manufacturers argued (and won) that the state couldn’t hire outside contractors to sift through paperwork to look for deceptive marketing practices. But the state’s supreme court just overturned that ruling, saying the pharma companies have no say in the state’s contracts with contractors.